Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics152
Neuroscience & CNS90
Immunology & Autoimmune80
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms149
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $1.0t | $1185.88 | -0.5% | 1.8M |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.6t | $259.31 | +1.1% | 3.7M |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $443.4b | $245.77 | +0.9% | 2.8M |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $315.6b | $127.95 | +0.2% | 5.1M |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $263.1b | $161.23 | +0.2% | 3.5M |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $212.2b | $588.67 | +2.4% | 1.3M |
 AMGN | Amgen Inc | Immunology & AutoimmuneRare Disease Therapeutics | $207.9b | $409.12 | +1.5% | 1.0M |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $161.7b | $133.19 | +1.7% | 6.2M |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $142.7b | $26.65 | +1.6% | 36.1M |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $133.4b | $64.02 | +0.7% | 5.0M |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $119.5b | $496.00 | +2.5% | 640.1K |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $78.2b | $777.31 | +1.6% | 462.9K |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $39.1b | $145.71 | +3.3% | 1.2M |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $38.7b | $233.88 | +2.7% | 695.5K |
 WAT | Waters Corp | Clinical-Stage Platforms | $36.8b | $406.90 | +1.8% | 643.6K |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $30.0b | $207.60 | +0.8% | 608.9K |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $27.5b | $218.44 | +1.4% | 1.5M |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $25.3b | $57.86 | -0.8% | 2.7M |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $24.5b | $353.96 | +1.6% | 356.8K |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $24.2b | $120.59 | +1.9% | 1.2M |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $24.1b | $35.08 | +3.4% | 5.8M |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $22.0b | $59.35 | +9.8% | 6.0M |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $21.9b | $529.94 | +1.1% | 915.5K |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $21.4b | $131.22 | -1.1% | 4.3M |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $16.9b | $162.52 | +2.2% | 825.0K |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $16.0b | $590.15 | +0.9% | 103.2K |
 ASND | Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $16.0b | $255.93 | +2.4% | 288.3K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $15.9b | $256.63 | -0.1% | 588.1K |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $15.7b | $84.50 | +2.0% | 1.5M |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $12.9b | $114.66 | +0.4% | 748.1K |
 ICLR | Icon Plc | Clinical-Stage Platforms | $12.6b | $164.33 | +2.2% | 312.2K |
 CORT | Corcept Therapeutics Inc. | Rare Disease Therapeutics | $12.4b | $111.03 | +2.6% | 492.8K |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $11.9b | $88.31 | +2.1% | 652.4K |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $11.6b | $62.50 | +3.7% | 3.8M |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $11.2b | $72.27 | +0.5% | 2.8M |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $11.2b | $211.84 | +1.2% | 667.1K |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $11.2b | $267.38 | +0.7% | 511.9K |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.1b | $504.00 | -0.3% | 310.9K |
 CYTK | Cytokinetics Inc. | Rare Disease TherapeuticsNeuroscience & CNS | $10.5b | $77.52 | -5.7% | 3.3M |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $10.4b | $13.97 | +3.1% | 1.9M |
 APGE | Apogee Therapeutics, Inc. Common Stock | Immunology & Autoimmune | $10.1b | $134.84 | +0.3% | 1.3M |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $10.1b | $325.69 | +1.0% | 122.2K |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $9.8b | $101.25 | +20.2% | 7.3M |
 BRKR | Bruker Corporation | Clinical-Stage Platforms | $9.6b | $52.88 | +4.2% | 1.8M |
 AVTR | Avantor, Inc. | Clinical-Stage Platforms | $9.3b | $13.60 | +3.1% | 5.1M |
 CRNX | Crinetics Pharmaceuticals, Inc. | Rare Disease Therapeutics | $8.8b | $84.17 | +0.2% | 1.8M |
 QGEN | QIAGEN N.V. | Clinical-Stage Platforms | $8.7b | $42.30 | +1.4% | 2.4M |
 IONS | Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $8.6b | $57.24 | +3.8% | 1.3M |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $8.5b | $366.00 | -2.6% | 396.7K |
 PTGX | Protagonist Therapeutics, Inc | Immunology & AutoimmuneMetabolic & Cardiometabolic | $8.5b | $145.81 | -0.2% | 221.9K |